Aihui Wang

Aihui Wang

Auto-generated profile, based on publicly available information

Aihui Wang

Stanford Univ, Dept Pathol, Stanford, CA USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2024 in Nature Immunology
Verified
Journal Article
Open access
PDF file
CYChristine Yiwen Yeh
Christine Yiwen Yeh
KAKarmen Aguirre
Karmen Aguirre
OLOlivia Laveroni
Olivia Laveroni
SKSubin Kim
Subin Kim
AWAihui Wang
Aihui Wang
LJLivnat Jerby
Livnat Jerby
The drivers of immune evasion are not entirely clear, limiting the success of cancer immunotherapies. Here we applied single-cell spatial and perturbational transcriptomics to delineate immune evasion in high-grade serous tubo-ovarian cancer. To this end, we first mapped the spatial organization of high-grade serous tubo-ovarian cancer by profiling more than 2.5 million cells in situ in 130 tumors from 94 patients. This revealed a malignant cell state that reflects tumor genetics and is predictive of T cell and natural killer cell infiltration levels and response to immune checkpoint blockade. We then performed Perturb-seq screens and identified genetic perturbations—including knockout of PTPN1 and ACTR8—that trigger this malignant cell state. Finally, we show that these perturbations, as well as a PTPN1/PTPN2 inhibitor, sensitize ovarian cancer cells to T cell and natural killer cell cytotoxicity, as predicted. This study thus identifies ways to study and target immune evasion by linking genetic variation, cell-state regulators and spatial biology.

26 April 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
CNCorrine Audrey Nief
Corrine Audrey Nief
PHPhoebe M. Hammer
Phoebe M. Hammer
AWAihui Wang
Aihui Wang
VCVivek Charu
Vivek Charu
ATAmina Tanweer
Amina Tanweer
BHBrooke E. Howitt
Brooke E. Howitt
Purpose: Risk prediction with genomic and transcriptomic data has the potential to improve patient outcomes by enabling clinicians to identify patients requiring adjuvant treatment approaches, while sparing low-risk patients from unnecessary interventions. Endometrioid endometrial carcinoma (EEC) is the most common cancer in women in developed countries, and rates of endometrial cancer are increasing. Experimental Design: We collected a 105-patient case-control cohort of stage I EEC comprising 45 patients who experienced recurrence less than 6 years after excision, and 60 Fédération Internationale de Gynécologie et d'Obstétrique grade-matched controls without recurrence. We first utilized two RNA-based, previously validated machine learning approaches, namely, EcoTyper and Complexity Index in Sarcoma (CINSARC). We developed Endometrioid Endometrial RNA Index (EERI), which uses RNA expression data from 46 genes to generate a personalized risk score for each patient. EERI was trained on our 105-patient cohort and tested on a publicly available cohort of 263 patients with stage I EEC. Results: EERI was able to predict recurrences with 94% accuracy in the training set and 81% accuracy in the test set. In the test set, patients assigned as EERI high-risk were significantly more likely to experience recurrence (30%) than the EERI low-risk group (1%) with a hazard ratio of 9.9 (95% CI, 4.1–23.8; P < 0.001). Conclusions: Tumors with high-risk genetic features may require additional treatment or closer monitoring and are not readily identified using traditional clinicopathologic and molecular features. EERI performs with high sensitivity and modest specificity, which may benefit from further optimization and validation in larger independent cohorts.

24 June 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
LULivia Ulicna
Livia Ulicna
SKSamuel C. Kimmey
Samuel C. Kimmey
CWChristopher M. Weber
Christopher M. Weber
GAGrace M. Allard
Grace M. Allard
AWAihui Wang
Aihui Wang
CRCapucine Van Rechem
Capucine Van Rechem
Subunits from the chromatin remodelers mammalian SWItch/Sucrose Non-Fermentable (mSWI/SNF) are mutated, deleted, or amplified in more than 40% of cancers. Understanding their functions in normal cells and the consequences of cancerous alterations will provide insight into developing new targeted therapies. Here we examined whether mSWI/SNF mutations increase cellular sensitivity to specific drugs. Taking advantage of the DepMap studies, we demonstrate that cancer cells harboring mutations of specific mSWI/SNF subunits exhibit a genetic dependency on translation factors and are sensitive to translation pathway inhibitors. Furthermore, mSWI/SNF subunits were present in the cytoplasm and interacted with the translation initiation machinery, and short-term inhibition and depletion of specific subunits decreased global translation, implicating a direct role for these factors in translation. Depletion of specific mSWI/SNF subunits also increased sensitivity to mTOR-PI3K inhibitors. In patient-derived breast cancer samples, mSWI/SNF subunits expression in both the nucleus and the cytoplasm was substantially altered. In conclusion, an unexpected cytoplasmic role for mSWI/SNF complexes in translation suggests potential new therapeutic opportunities for patients afflicted by cancers demonstrating alterations in their subunits. Significance: This work establishes direct functions for mSWI/SNF in translation and demonstrates that alterations in mSWI/SNF confer a therapeutic vulnerability to translation pathway inhibitors in cancer cells.

22 June 2022 in Cancer Cytopathology
Verified
Journal Article
Closed access
YZYili Zhu
Yili Zhu
AWAihui Wang
Aihui Wang
GAGrace M. Allard
Grace M. Allard
JNJoshua J. Nordberg
Joshua J. Nordberg
RNRamesh V. Nair
Ramesh V. Nair
ALAlarice C. Lowe
Alarice C. Lowe

30 September 2024 in Medical Image Analysis
Verified
Journal Article
Closed access
NGNegar Golestani
Negar Golestani
AWAihui Wang
Aihui Wang
GMGolnaz Moallem
Golnaz Moallem
GBGregory R. Bean
Gregory R. Bean
MRMirabela Rusu
Mirabela Rusu

4 September 2023
Verified
Conference Paper
Closed access
HDHuichao Duan
Huichao Duan
AWAihui Wang
Aihui Wang
XXXiufen Xin
Xiufen Xin
In recent years, there has been an increase in the number of patients with motor dysfunction due to neurological disorders such as stroke and spinal cord injury. Existing rehabilitation medical resources are unable to provide one-on-one rehabilitation treatment for patients. Lower limb rehabilitation robots (LLRRs) are used as assistants to rehabilitation physicians to help patients with rehabilitation training by simulating the walking gait of a normal person. Each patient’s individual degree of impairment varies from person to person, and the parameters of the lower extremity differ, which leads to different rehabilitation training programs used by the patient. Therefore, how to tailor the reference trajectory for patients according to their physical and gait parameters becomes the focus of research at this stage. In this paper, a gait generation model based on GLS network is designed to provide continuous personalized gait trajectories for patients. The GLS network is composed of an LSTM (Long Short-Term Memory) network based on the gap loss function and a sparrow search algorithm (SSA).The gap loss is presented based on the difference between the initial angle and the end joint angle of each cycle. The experimental results are analyzed by mean absolute deviation (MAD). The experimental results show that the gait trajectory generated by the GLS network reduces the experimental error by 16.9 % compared to the trajectory generated by the conventional algorithm (PSO). Therefore, our proposed GLS network-based generation of personalized continuous gait trajectories generates gait trajectories that are more similar to the actual gait trajectories.